BiologicsHQ Team

BiologicsHQ
Team

Robert S. Schwartz, Ph.D. Chair, New York - Bob has extensive experience litigating biotechnology and pharmaceutical patents, including those relating to antibodies, protein biochemistry, molecular biology, genomics and proteomics. Bob has a B.S. in Biology and a Ph.D. in Biochemistry. As a Principal Investigator of grant-funded research he published more than 40 articles in peer-reviewed publications and 7 book chapters. Read Full Bio
Ha Kung Wong Partner, New York - Ha Kung has extensive experience litigating a wide variety of pharmaceutical cases, including those concerning biologics used to treat rheumatoid arthritis and autoimmune disorders.  He also has extensive experience consulting, conducting due diligence and licensing pharmaceutical portfolios.  Ha Kung has a B.S. in Biochemistry and a B.S. in Chemistry. Read Full Bio
April Breyer Menon Consultant, Illinois - April has litigated various pharmaceutical and biotechnology cases, including concerning oncology treatments and DNA sequencing technology.  She has specialized in damages and commercial success arguments.  April has a B.S. in Genetics, Cell Biology and Development and a B.A. in Physiology. Read Full Bio
Katherine Adams Counsel, New York - Katie has experience litigating a variety of pharmaceutical and biotechnology patents, including those relating to treatments for oncology and genetic disorders.  Katie received a B.S. degree in Neuroscience with high honors. Read Full Bio
Christopher P. Borello Partner, New York - Chris has extensive experience litigating  and counseling clients on biotechnology and pharmaceutical patents including those relating to fusion proteins, immunomodulators, genetically modified animals, antibodies, chemical compounds, prodrugs and formulations.  Chris has undergraduate and advanced degrees in engineering. Read Full Bio
Christopher E. Loh Partner, New York - Christopher has extensive experience counseling clients and litigating matters involving biotechnology and life sciences, including in the areas of antibody biosimilars, targeted cancer therapies, diabetes treatments and siRNA technologies.  Christopher has a B.S. in Molecular Biochemistry and Biophysics and in Economics from Yale University. Read Full Bio
Sean McDonagh Counsel, New York - Sean has experience litigating and prosecuting biologics, biotechnology and pharmaceutical patents. Sean has a B.S. in Human Biology, and an M.S. in Physiology.  His graduate work focused on the neurophysiology of the glucagon-like peptide hormones and was published in the American Journal of Physiology. Read Full Bio
Whitney Meier Howard Partner, New York - Whitney has experience litigating biochemistry, biotechnology, and pharmaceutical formulation patents.  Whitney was awarded a B.S. degree in Biochemistry with high distinction. Read Full Bio
Damineh Morsali, Ph.D. Associate, New York - Damineh has experience with pre-suit investigations, patent litigation, ITC proceedings, licensing, and due diligence analysis in an array of technologies, including biologics, RNA interference, biotechnology, pharmaceuticals, and medical devices. She has a PhD in Neuropharmacology from Oxford University and a B.S. in Molecular Genetics from King’s College, University of London, with Honors. She held multiple post-doctoral research positions at world-renowned universities and has authored a number of publications and book chapter. Read Full Bio
Scott K. Reed Partner, New York - Scott has more than 30 years of trial experience and has served as lead trial counsel in a wide range of complex biotechnology, pharmaceutical, and chemical cases, including those relating to cell-based biotechnology assays, fusion proteins, and angiogenesis.   Scott's undergraduate degrees are in Chemistry and Economics. Read Full Bio
Alicia A. Russo Partner, New York - Alicia has extensive experience litigating and prosecuting biologics, biotechnology, bioinformatics and pharmaceutical patents.  She has a B.S. in Biology and Chemistry, and an M.S. in Biomedical Sciences.  Alicia has published original papers in Science, Nature, Cell and the Proceedings of the National Academia of Sciences. Read Full Bio

Methodology

Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

    captcha